2026 FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meeting

The 2026 FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meeting is a pivotal event organized by the U.S. Food and Drug Administration (FDA). This committee is dedicated to reviewing and evaluating data concerning the safety, effectiveness, and appropriate use of human cells, tissues, gene transfer therapies, and xenotransplantation products intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases, as well as in the reconstruction, repair, or replacement of tissues for various conditions.

The meeting will cover key topics such as the latest advancements in cellular therapies, tissue transplantation, gene transfer therapies, and xenotransplantation. Discussions will focus on evaluating new research findings, assessing clinical trial data, and considering regulatory pathways for emerging therapies. The agenda will also include deliberations on the ethical implications and safety concerns associated with these innovative treatments.

Attendees will have opportunities to engage in networking sessions, participate in panel discussions, and attend presentations by leading experts in the field. The event will feature an expo hall showcasing the latest technologies and products related to cellular, tissue, and gene therapies. Notable speakers will include prominent researchers, clinicians, and regulatory officials who will share their insights and experiences.

This meeting is essential for healthcare professionals, researchers, industry representatives, and policymakers involved in the development, regulation, and application of cellular, tissue, and gene therapies. Participation will provide valuable insights into current trends, regulatory considerations, and future directions in these rapidly evolving fields.